China's Condom Market Opens Up For LIG's Durex

3 March 1998

Given China's huge 1.3 billion population and its restrictive laws onthe number of children couples are allowed (ie one), it is a huge contraceptive market. And early this month, the government changed tactics opening, for the first time, its condom market to foreign companies.

As things stand, the preferred method of contraception in China is sterilization, despite the fact that condoms are given out gratis. However, local products are seen to be of poor quality, and it is thought that with the growing affluence of the Chinese population, people will be ready to pay themselves for better-quality, more reliable contraceptives.

Among the first to benefit from the Chinese change of legislation is the UK-based London International Group, the manufacturer of the world's leading condom brand, Durex. Reportedly, after two years of talking to the Chinese authorities, LIG has now signed a $7 million 50/50 joint venture deal with Qingdao Latex Company to start producing condoms in that country. LIG has said it will be applying standard western quality control systems to the venture.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight